Lungpacer Medical announced that it received FDA investigational device exemption (IDE) approval to begin a trial for its ...
Hosted on MSN1mon
Alpha Tau announces FDA approval of IDE supplementFDA, of an Investigational Device Exemption IDE, supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first ...
"Receiving an IDE from the FDA is a landmark achievement for Newronika," said Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika. "It affirms the potential of our adaptive DBS system to fill an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results